

AR 226-1495

TAFT, STETTINIUS & HOLLISTER LLP

80pp

425 WALNUT STREET, SUITE 1800
CINCINNATI, OHIO 45202-3957

513-381-2838

FAX: 513-381-0205

www.taftlaw.com

COLUMBUS, OHIO OFFICE
TWELFTH FLOOR
21 EAST STATE STREET
COLUMBUS, OHIO 43215-4221
614-221-2838
FAX: 614-221-2007

NORTHERN KENTUCKY OFFICE
SUITE 340
1717 DIXIE HIGHWAY
COVINGTON, KENTUCKY 41011-4704
609-331-2838
513-381-2838
FAX: 513-381-6613

CLEVELAND, OHIO OFFICE
3500 BP TOWER
200 PUBLIC SQUARE
CLEVELAND, OHIO 44114-2302
216-241-2838
FAX: 216-241-3707

ROBERT A. BILOTT
(513) 357-9638
bilott@taftlaw.com

May 6, 2003

Dr. Charles M. Auer
Chemical Control Division
Office of Prevention, Pesticides and Toxic
Substances
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue, N.W.
Mail Code 7405M
Washington, DC 20004

TELECOPY
Jennifer Seed
U.S. Environmental Protection Agency
410 M Street, S.W.
Washington, DC 20460

Christopher Jones, Esq.
Director
Ohio Environmental Protection Agency
122 South Front Street
Columbus, OH 43215

Thomas V. Skinner
Regional Administrator
U.S. Environmental Protection Agency
77 West Jackson Blvd.
Chicago, IL 60604

Oscar Hernandez
Director, Risk Assessment Division
Office of Prevention, Pesticides and Toxic
Substances
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue, N.W.
Mail Code 7405M
Washington, DC 20460

John Wheeler, Ph.D. (E-29)
ATSDR
1600 Clifton Road, N.E.
Atlanta, GA 30333

Donald S. Welsh
Regional Administrator
U.S. Environmental Protection Agency
Region III
1650 Arch Street
Philadelphia, PA 19103-2029

Re: Human Health Threat Arising From Releases Of PFOA/APFO/C-8 In
West Virginia And Ohio

RECEIVED
OPT NCIC
2003 SEP -5 PM 12:09

CONTAIN NO CRI


000001

May 6, 2003
Page 2

Ladies and Gentlemen:

As a follow up to our letters of February 3, April 4, and April 11, 2003 regarding the potential health threat to those living near the Washington Works plant of E.I. duPont de Nemours and Company located in Wood County, West Virginia, we have enclosed copies of the following documents relating to the health condition of workers at that DuPont plant where C-8 has been used in manufacturing processes since the early 1950s:

1. DuPont Internal Report, "Study Of Myocardial Infarction At Washington Works Plant" (1975) (DUPONT910-918);^{1/} and
2. E.I. duPont de Nemours and Company's Objections And Response To Plaintiffs' Third Set Of Interrogatories And [Sixth] Set Of Requests For Production Of Documents (April 28, 2003).^{2/}

Very truly yours,

Robert A. Bifott

RAB/mdm
Enclosures

cc: R. Edison Hill, Esq. (w/o encls.)
Larry A. Winter, Esq. (w/o encls.)
Gerald J. Rapien, Esq. (w/o encls.)
Mary Dominiak, (USEPA, OPPT) (for inclusion in AR-226) (w/ encls.) (by telecopy and Federal Express)

^{1/} As a Defendant in a class action lawsuit pending against DuPont in the West Virginia State Court in which we serve as Class counsel, DuPont has the right to mark documents produced in that case as falling under the terms of the Stipulated Protective Order that allows parties to limit distribution of documents, if they qualify as documents for which "confidential business information" (CBI), protection would be available under, among other provisions, 40 C.F.R. Part 2, Subpart B. Although DuPont originally marked this document as confidential under that Order, DuPont has since confirmed in writing that it has withdrawn its confidentiality claim with respect to this report.

^{2/} Exhibit B to this set of DuPont's discovery responses has been removed, because the document has been marked "confidential" under the terms of the Stipulated Protective Order referenced above in Footnote 1. We are currently challenging DuPont's confidentiality claim with respect to that document but the issue has not yet been resolved.

000002